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Introduction 
Peripheral Blood
Peripheral blood cells are the cellular components of  blood, con-
sisting of  red blood cells, white blood cells, and platelets, which 
are found within the circulating pool of  blood and not sequestered 
within the lymphatic system, spleen, liver, or bone marrow. Stem 
cells are small, round cells with a squat nucleus and scant surround-
ing cytoplasm. Although unremarkable in appearance, stem cells 
can perform what have been called "acts of  biological resurrection."
Whereas other types of  cells in the body have a limited lifespan and 
die after dividing their endowed number of  times, a stem cell can 
reproduce forever. The stem cell is immortal (in cellular terms). A 
stem cell can forgo immortality and turn into an ordinary blood cell, 
a red blood cell (an erythrocyte), a white blood cell (a leukocyte), 
or a large cell (a megakaryocyte) that fragments into the platelets 
needed for blood to clot. All stem cells, regardless of  their source
share three general properties: they are able of  dividing and re-
newing themselves for long period, they are unspecialized and 
they are able to differentiate into any specialized cell types. The 
real pluripotent stem cells are issued from the embryo. Specifically, 
embryonic stem cells are derived from eggs fertilized in vitro and 
isolated from a microscopic ball of  cells, the blastocyst, formed 
four or five days after the fertilization. These cells can give rise to 
every tissues of  the human body and represent a huge reservoir 
of  regenerative cells. But for some ethical consideration as well as 
some hazards appeared during embryonic stem cells transplanta-
tion (high incidence of  teratoma or terat ocarcinoma), research-
ers have redirected their attention upon primitive cells residing 
in the adult body. Each organ and tissue is perceived to possess 
a sub-population of  cells capable of  self  maintenance activated 
for the normal turnover of  tissue or in case of  organ injury.
The stem cell extraction and isolation methods from Pe-
ripheral blood
Approximately 100 ml of  healthy adult peripheral blood was col-
Abstract
Blood and the system that forms it, known as the hematopoietic system, consist of  many cell types with specialized functions. Red 
blood cells (erythrocytes) carry oxygen to the tissues. Platelets (derived from megakaryocytes) help prevent bleeding. Granulocytes 
(neutrophils, basophils and eosinophils) and macrophages (collectively known as myeloid cells) fight infections from bacteria, fungi, 
and other parasites such as nematodes (ubiquitous small worms). Some of  these cells are also involved in tissue and bone remodeling 
and removal of  dead cells. B-lymphocytes produce antibodies, while T-lymphocytes can directly kill or isolate by inflammation cells 
recognized as foreign to the body, including many virus-infected cells and cancer cells. Many blood cells are short-lived and need to be 
replenished continuously; the average human requires approximately one hundred billion new hematopoietic cells each day. The con-
tinued production of  these cells depends directly on the presence of  Hematopoietic Stem Cells (HSCs), the ultimate, and only, source 
of  all these. Peripheral blood stem cells (PBSC) are rapidly becoming the primary rescue modality for autologous transplantation and 
are now actively being investigated in the allogeneic transplant setting. Many investigators and clinical researchers believe that PBSC 
are likely to replace bone marrow stem cells entirely, for use in clinical transplantation in the not too distant. Hematopoietic stem cells 
(HSCs) are the blood cells that give rise to all the other blood cells. They give rise to the myeloid (monocytes and macrophages, neutro-
phils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-cells, NK-cells). 
The definition of  hematopoietic stem cells has changed in the last two decades. The hematopoietic tissue contains cells with long-term 
and short-term regeneration capacities and committed multipotent, oligopotent, and unipotent progenitors. 
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lected in K2Epreloaded tubes. Bloods samples were processed as 
soon as possible on the day of  collection according to two differ-
ent protocols to isolate the EPC. For the ‘direct’ approach, unma-
nipulated human blood was diluted in EGM and directly placed in 
culture, as described by Reinish et al. This approach expected EPC 
colony formation after 1-2 weeks For the alternative approach, the 
MNCs fraction was isolated from human blood by density-gradi-
ent centrifuging. Isolated MNCs were then placed in culture and 
EPC colony formation was expected after 3-4 weeks in culture
Multi Lineages Differentiation Potential
Last but not least, the more important point is the capacity of  
stem cells to differentiate into other lineages to permit the re-
generation of  specific organ. As classical source of  HSC, the 
majority of  the experiments have been realized from bone mar-
row. It has been demonstrated that UCB-SC contain the largest 
percentage of  the most immature pluripotent CD34+ cells which 
can react more strongly to in vitro cytokine stimulation and pro-
duce a lot of  progeny cells. From the results, the authors showed 
that UCB-SC have the better ability to self-renew and to give 
rise to large clones of  primitive progeny. These results confirm 
that the larger proportion of  primitive HSC reside in the UCB 
and could adopt different lineages. Recently, thanks to microar-
ray technology, the powerful tool which permits the profiling of  
thousand of  genes in one single experiment, we start to better un-
derstand the molecular mechanisms which regulate HSC activity
Availability of  HSC
The number of  stem cells in the adult is very low. The propor-
tion of  HSC differs according to the source: the largest fraction 
in the BM and the poorest in the UCB38. Nevertheless, as shown 
previously6, the proportion of  HSC in the PB could be dramati-
cally increased by injection of  cytokine such as rhG- CSF prior to 
the collection without any risk for the patient. Besides, recently, 
improvement in HSC mobilization has been achieved by the use 
of  AMD3100, a selective antagonist of  CXCL12, also known 
as stromal cell derived factor-1 (SDF-1) that binds to its recep-
tor CXCR4 expressed on CD34+ cells surface. It is indeed well-
known that SDF-1 plays a central role in CD34+ homing in the 
BM and AMD3100, by decreasing the interactions between SDF-
1 and CXCR4 induces rapid stem cells mobilization in the circu-
lating blood and could as well acts synergistically with rh-G-CSF.
Peripheral blood stem cell (PBSC) collection
Peripheral blood stem cell (PBSC) collection is a procedure 
where volunteer donors or patients donate their stem cells 
through apheresis for allogeneic and autologous blood and 
marrow transplantation. At Children’s, most PBSC collec-
tions are for autologous transplants. A variety of  diseases are 
treated particularly neuroblastoma and malignant brain tumors
Stem cell apheresis
Apheresis is the process of  extracting blood components from 
the peripheral blood with the help of  a cell separator that divides 
blood into separate cell elements. Because few stem cells travel in 
the bloodstream, it takes several hours (most within one day) to 
collect a sufficient quantity for transplantation. Children’s uses cut-
ting-edge monitoring equipment in the Hematopoietic Stem Cell 
Laboratory that allows the stem cell transplant team to know pre-
cisely when, in real time during the procedure, the optimum quan-
Comparison between Peripheral Blood Stem Cells and Cord Blood Donated for Transplantation 
 
Peripheral Blood Cord Blood
Bone marrow donation requires surgery under general anesthesia. Donors may ex-
perience temporary discomfort and/or pain. Long-term consequences of  growth 
factors used in peripheral blood stem cell donations are uncertain.
When obtained from the delivered placenta and umbilical cord, cord blood dona-
tion poses no medical risk to mother or infant
A transplant requires donation of  a quart or more of  bone marrow (mixed with 
blood).
A small volume (sometimes few ounces) can be used for transplantation. The 
number of  cells needed depends on the recipient’s weight.
Bone marrow and peripheral blood grafts contain large numbers of  stem cells. 
Engraftment of  neutrophils is rapid.
Cord blood units contain smaller numbers of  stem cells. Slower engraftment may 
lead to prolonged hospital stay, and in certain cases, to serious complications.
After a formal search is started, it usually takes 2 or more months to transplant, if  
a donor is available. 
When a match is found, it can take only a few days for confirmatory and special 
testing for shipment to the Transplant Center (less than 24 hours in an emer-
gency). 
Potential donors may no longer be available or may have withdrawn consent. 
Donor must be found and retested to confirm the HLA typing and infectious dis-
ease results and to confirm that the donor is still willing and able to donate bone 
marrow. Significant donor attrition. 
Once frozen, a cord blood unit is available until used. There is no donor attrition. 
Donor may be available to give a second transplant or to donate blood for T-cells 
if  necessary. 
Donor is not available for a second donation
Bone marrow is used fresh (shelf-life measured in hours). Peripheral blood stem 
cells usually stored for short term (days to a few months). 
Cord blood units are cryopreserved (stored in special freezers). Frozen cord blood 
has been transplanted successfully after up to 13 years in storage.
Patient must begin conditioning before the bone marrow or peripheral bloods 
harvest. Coordination between donation and transplant is critical and complex.
Cord blood graft can be shipped to the transplant center before the patient enters 
the hospital and begins conditioning for transplantation. Coordination is simple. 
Cord blood units are shipped on demand. 
Latent viral infection in the donor is common (i.e. CMV > 50% in U.S. adult 
donors).
Latent viral infection in the cord blood donor is rare (i.e. CMV <1% in U.S.).
No risk of  transplanting a genetic disease. There is a small probability that a rare, unrecognized genetic disease affecting the 
blood or immune system of  the baby may be given with the cord blood transplant.
Severe graft vs host disease (GvHD) is common with mismatched grafts. GvHD less frequent, usually less severe and easier to treat
Generally requires a perfect match between donor and recipient for 8/8 HLA-A, 
-B, -C and -DRB1 antigens. Additional HLA factors (HLA-DQ and -DP) increas-
ingly used to improve prognosis. 
HLA-mismatched cord blood transplants are possible, making it easier to find a 
suitable match. Role of  HLA-C, -DQ and -DP are not yet known. 
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tity of  stem cells have been collected. Infants and young children 
may require ongoing sedation during the apheresis procedure, and 
in these cases only, stem cell collections occur in the pediatric in-
tensive care unit (PICU). Older children undergo apheresis in the 
Blood and Marrow Transplantation inpatient unit at the hospital
25 years of  peripheral blood stem cell transplantation
It has been 25 years since peripheral PBSCT was introduced 
as a transplant modality. This anniversary, therefore, marks the 
first clinical evidence that circulating hematopoietic stem cells 
are capable of  completely and permanently regenerating a lym-
phohematopoietic system after myeloablative treatment. Even 
more fundamental and Beyond transplant aspects, the capabil-
ity of  hematopoietic blood stem cells to regenerate And main-
tain equal cellular concentration throughout all marrow spaces 
in the human body attributes to them a homeostatic function 
that had until then never been shown Before in a clinical setting.
First successful autologous PBSCTs
The autologous transplant modality required a liquid nitro-
gen cryopreservation technique for large volume leukapheresis 
products. Such a method was developed allowing stem cells to 
accumulate over the course of  several daily collections until an 
engraftment dose was reached. Thus, with the apheresis and 
cryopreservation technologies in place, blood stem cell infusions 
were first attempted in 1981 at Hammersmith Hospital in Lon-
don, England, in patients with accelerated phase chronic myeloid 
leukemia (CML); the patients’ stem cells had been harvested 
in earlier chronic phase with the intent of  achieving a second 
chronic phase.[15] In the same year, at Johns Hopkins Hospital 
in Baltimore, Maryland, a “normal” blood stem cell harvest and 
transplantation attempt was undertaken in a patient with CML in 
cytogenetic remission. After myeloablative treatment and blood 
stem cell infusion there was first evidence of  fast and complete 
hematopoietic reconstitution, although long-term stem cell 
engraftment could not be documented. It was another 5 years 
in 1986, before a patient with Burkitt’s lymphoma underwent
myeloablative radio- and chemotherapy followed by PBSCT at 
Heidelberg University Hospital in Germany. Hematopoietic re-
constitution was fast and complete. Twenty-five years later, the 
patient remains alive without evidence of  disease and with nor-
mal lymphohematopoietic function. In 1986 and 1987, similar 
reports of  successful PBSCTs were documented by research
groups at the University of  Nebraska Medical Center,[18] 
the Hospital Haut Leveque in Bordeaux, France,[19] and 
the Royal Adelaide Hospital in Adelaide, Australia.[20]
In all of  those initial PBSCT cases, stem cells were col-
lected by multiple apheresis procedures at steady state with-
out hematopoietic growth factor mobilization treatment.
Strategies to increase peripheral blood stem cell concentra-
tion
In contrast to the well established BM transplantation, the 
use of  PB stem cells in the mid 1980s seemed cumbersome 
mainly because in non-CML patients numerous steady state 
apheresis procedures were required to achieve an engraft-
ment stem cell dose. For PBSCT to be accepted as a main-
stream treatment modality, strategies to temporarily increase 
PB stem cell concentration had to be developed. One strategy 
was to induce a rebound of  PB stem cell concentration follow-
ing non-myelotoxic chemotherapy and short-term myelosup-
pression. Another strategy was to temporarily expand the PB 
stem cell pool by administering hematopoietic growth factors.
Results
We still cannot say with certainty if  the fibroblastoid cells (fibro-
blast-like) that can be obtained through liquid culture of  peripheral 
blood are the same cells as fibrocytes or circulating mesenchymal 
cells, because the surface markers, concretely CD34 –which is an 
indicator of  the status as a hemopoyetic stem cell–, are expressed 
in fibrocytes[5] and in the cells described by Zhao et al[7] and is 
negative in mesenchymal cells[6]. Our results show evidence of  
a clear expression of  CD34+ in fibroblastlike cells that, in addi-
tion to the positivity to vimentin (a connective tissue marker) and 
the NBT-test (an indicator of  phagocytic activity), points to a cell 
with common characteristics of  the stem cells, monocytes-mac-
rophages, and fibroblasts. The lack of  uniformity in the expres-
sion of  surface markers, as documented in the scientific literature, 
certainly is related to the variability of  the culture conditions, in-
cluding the number of  seeded cells, the culture media, the con-
centration of  bovine fetal serum, the culture periods, stimulation 
factors for differentiation, and the methods for detecting surface 
markers (immunocytochemistry or flux activated cytometry).
Conclusion
Among the HSC, we have reviewed the numerous advantages of  
the UCB subset as these cells are easily accessible by a non inva-
sive collection process, in vitro amplifiable, well-tolerated and last 
but not least possess more primitive molecular characteristics that 
confer them a higher flexibility. Significant progress have been 
made in recent years by the use of  three-dimensional collagen or 
fibronectin porous scaffolds which promote new tissue formation 
by providing a surface and void volume that promote the attach-
ment, proliferation and differentiation of  the stem cells. Neverthe-
less, tissue engineering is currently only used in a limited number 
of  clinical applications as bioengineered skin for burns. It may be 
unnecessary first to isolate and differentiate HSC in vitro but rather 
to mobilize endogenous stem cells from the circulating blood to 
home to the damaged area. Some experiments with animals have 
shown encouraging results by injecting growth factors to mobilize 
endogenous stem cells to the site of  injury in a model of  heart 
damage. In summary, the different approaches for tissue engineer-
ing are very promising and undoubtedly, HSC will play a key role 
in the development of  cellular therapy for a variety of  diseases. 
However, the biological properties and the interactions between 
stem cells and their environment have to be more investigated 
to be able, soon, to control their destiny in an appropriate way.
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